Dana D. Hu-Lowe
Corresponding Author: Dana Hu-Lowe
Oncology Translational Research
Pfizer Inc.
10777 Science Center Dr.
Name/email consistency: high
- The Discovery and Development of SU14813, a Next-Generation Multitargeted Tyrosine Kinase Inhibitor for the Treatment of Human Malignancies. Hu-Lowe, D., Brega, N., Patyna, S. Mol. Cancer Ther. (2011)
- Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapies. Hu-Lowe, D.D., Chen, E., Zhang, L., Watson, K.D., Mancuso, P., Lappin, P., Wickman, G., Chen, J.H., Wang, J., Jiang, X., Amundson, K., Simon, R., Erbersdobler, A., Bergqvist, S., Feng, Z., Swanson, T.A., Simmons, B.H., Lippincott, J., Casperson, G.F., Levin, W.J., Stampino, C.G., Shalinsky, D.R., Ferrara, K.W., Fiedler, W., Bertolini, F. Cancer Res. (2011)
- Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Hu-Lowe, D.D., Zou, H.Y., Grazzini, M.L., Hallin, M.E., Wickman, G.R., Amundson, K., Chen, J.H., Rewolinski, D.A., Yamazaki, S., Wu, E.Y., McTigue, M.A., Murray, B.W., Kania, R.S., O'Connor, P., Shalinsky, D.R., Bender, S.L. Clin. Cancer Res. (2008)
